2-chloro-4-isocyanato-3-methyl-benzonitrile | 627531-80-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-4-isocyanato-3-methyl-benzonitrile
• 英文别名: 2-chloro-4-isocyanato-3-methylbenzonitrile；3-chloro-4-cyano-2-methylphenyl isocyanate；3-chloro-4-isocyanato-3-methylbenzonitrile；4-isocyanato-3-methyl-2-chlororbenzonitrile
• CAS: 627531-80-0
• 化学式: C₉H₅ClN₂O
• 分子量: 192.605
• InChiKey: WSLHOMVZQPRIMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  53.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-4-isocyanato-3-methyl-benzonitrile 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 (2R,3R)-3-(tert-butyldimethylsilanyloxy)-2-[(1R)-(2,2,2-trifluoro-1-hydroxyethyl)]-pyrrolidine-1-carboxylic acid (3-chloro-4-cyano-2-methyl-phenyl)-amide
  参考文献：
  名称：

  Bicyclic modulators of androgen receptor function

  摘要：

  本发明涉及按照式I的双环化合物，包含这种化合物的药物组合物以及使用这种化合物治疗与雄激素受体相关疾病的方法，例如与年龄相关的疾病，例如肌少症，其中R1、R2、R5、X、Y和n在此处定义。

  公开号：

  US20050197359A1
• 作为产物：
  描述：

  3-氯-2-甲基乙酰苯胺 在 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 盐酸 、 溴 、 碳酸氢钠 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-4-isocyanato-3-methyl-benzonitrile
  参考文献：
  名称：

  Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

  摘要：

  Pharmacokinctic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.076

文献信息

• [EN] MONOCYCLIC N-ARYL HYDANTOIN MODULATORS OF ANDROGEN RECEPTOR FUNCTION<br/>[FR] MODULATEURS D'HYDANTOINE N-ARYL MONOCYCLIQUES DE LA FONCTION DU RECEPTEUR D'ANDROGENE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005049580A1

  公开（公告）日：2005-06-02

  The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a patient in need of therapy for an androgen receptor associated condition by administering a therapeutically effective amount of at least compound of the present invention.

  本发明涉及一种新型化合物，用于治疗与雄激素受体相关的疾病，如与年龄相关的疾病，包含至少一种本发明化合物的药物组合物，以及通过给予至少一种本发明化合物的治疗有效量来治疗需要治疗雄激素受体相关疾病的患者的方法。
• [EN] SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS DE SPIROHYDANTOÏNE ET LEUR UTILISATION COMME MODULATEURS SÉLECTIFS DES RÉCEPTEURS DES ANDROGÈNES
  申请人：NOVARTIS AG

  公开号：WO2013128421A1

  公开（公告）日：2013-09-06

  The present invention relates to a compound of formula (1-1 ) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明涉及一种化合物，其化学式为(1-1)，其以自由形式或药用可接受盐形式存在，其中取代基如规范中所定义；涉及其制备，其用作药物以及包含它的药物。本发明还提供了一种药理活性剂的组合和药物组成。
• Electrocatalytic Generation of Amidyl Radicals for Olefin Hydroamidation: Use of Solvent Effects to Enable Anilide Oxidation
  作者：Lin Zhu、Peng Xiong、Zhong-Yi Mao、Yong-Heng Wang、Xiaomei Yan、Xin Lu、Hai-Chao Xu

  DOI：10.1002/anie.201510418

  日期：2016.2.5

  important amidyl radicals from N−H amides is an appealing and yet challenging task. Previous methods require a stoichiometric amount of a strong oxidant and/or a costly noble‐metal catalyst. We report herein the first electrocatalytic method that employs ferrocene (Fc), a cheap organometallic reagent, as the redox catalyst to produce amidyl radicals from N‐aryl amides. Based on this radical‐generating

  由N-H酰胺氧化生成重要的合成酰胺基自由基是一项有吸引力且具有挑战性的任务。先前的方法需要化学计量的强氧化剂和/或昂贵的贵金属催化剂。我们在此报告了第一种电催化方法，该方法采用廉价的有机金属试剂二茂铁（Fc）作为氧化还原催化剂，以从N-芳基酰胺生成酰胺基。基于这种自由基生成方法，已经开发了一种有效的分子内烯烃加氢酰胺化反应。
• Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such
  申请人：Nique Francois

  公开号：US20100063120A1

  公开（公告）日：2010-03-11

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  式(I)的化合物：其中X为O或S，R1为酰基，醛基，环烷基，或可选择地取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基，或卤代炔基；或R3和R4形成一个，可选择的芳香或杂环，可选择地取代的环，R5为H，卤素，三氟甲基，-CN，或-NO2；R3，R4和R5中不全为H，R6和R9为H，卤素，羟基；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基，或炔基；R7和R8为H，卤素，羟基，硫氢基；烷氧基或烷硫基，可选择地由羟基和/或卤素取代；R7和R8中的一个不为H或卤素；或R7和R8中的一个为药用可接受的酯或硫酯基团，或R6为C1-3-烷基或，与R1或R2中的任一者一起，代表C1-3烷基或烯基链连接基，可选择地由甲基，三氟甲基，羟基，或卤素取代，以及其药用可接受的盐和酯，可用作选择性雄激素调节剂。
• [EN] BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION<br/>[FR] MODULATEURS BICYCLIQUES DE FONCTION DE RECEPTEURS D'ANDROGENES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005087232A1

  公开（公告）日：2005-09-22

  The present invention relates to bicyclic compounds according to formula (I), pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.

  本发明涉及公式（I）所示的双环化合物，包含这种化合物的制药组合物以及使用这种化合物治疗与雄激素受体相关疾病的方法，例如与年龄相关的疾病，如肌肉萎缩症等，其中R1，R2，R5，X，Y和n在此定义。